Join our daily newsletter At The Bell to receive exclusive market insights
- Synthetic antibiotic company Recce Pharmaceuticals (RCE) has received positive animal trial data for its kidney infection and UTI treatment
- The trial in rats showed the RECCE 327 antibiotic significantly reduced the level of e-coli bacteria in both the kidneys and the bladder
- E-coli is a bacteria often responsible for urinary tract infections, or UTIs, which can progress to kidney infections and even blood poisoning
- The therapy was developed to combat antibiotic-resistant superbugs
- Shares in Reece Pharmaceuticals have risen 10.2 per cent today, worth 48.5 cents each
Synthetic antibiotic company Recce Pharmaceuticals (RCE) has received positive animal trial data for its superbug-resistant antibiotic.
The patented therapy, Recce 327, was developed to combat blood infections and sepsis from E.coli and S.aureus bacteria and their antibiotic-resistant forms.
Recce Pharmaceuticals is initially focusing on the antibiotics’ potential to combat sepsis.
The recent trial in rats showed the RECCE 327 antibiotic significantly reduced the level of e-coli bacteria in both the kidneys and the bladder.
This bacteria is often responsible for urinary tract infections (UTI) which can progress to kidney infections and even sepsis.
“These data support the use of RECCE 327 across the full therapeutic road map for pre-sepsis and sepsis conditions, now including the treatment of primary infection by E. coli in kidney and UTIs,” said Chairman Dr John Prendergast.
“This further justifies the exciting potential of RECCE 327 as a new class of antibiotics as we continue to gather new data ahead of our first in-human clinical studies,” he said.
Shares in Reece Pharmaceuticals have risen 10.2 per cent today, worth 48.5 cents each.
